









Markets
/
Stocks
/
nasdaq-scyx
/

SCYNEXIS Inc

SCYX

0.631USD

+0.001+0.14%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

24.72MMarket Cap

LossP/E TTM



SCYNEXIS Inc

0.631

+0.001+0.14%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of SCYNEXIS Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

SCYNEXIS Inc's Score

Industry at a Glance

Industry Ranking

102 / 159

Overall Ranking

261 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.667

Target Price

+481.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

SCYNEXIS Inc Highlights

StrengthsRisks

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.75M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -1.59, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 9.89M shares, decreasing 26.96% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 159.80K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.39, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.36M, representing a year-over-year increase of 85.33%, while its net profit experienced a year-over-year increase of 52.38%.

Score

Industry at a Glance

Previous score

6.39

Change



Financials

7.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.58

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.12

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

SCYNEXIS Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.64, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -1.59, which is -361.58% below the recent high of 4.17 and -107.37% above the recent low of -3.30.

Score

Industry at a Glance

Previous score

7.64

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 102/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for SCYNEXIS Inc is 4.00, with a high of 4.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

3.667

Target Price

+481.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

SCYNEXIS Inc

SCYX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.03, which is lower than the Pharmaceuticals industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 0.82 and the support level at 0.53, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.20

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.018

Sell

RSI(14)

25.106

Sell

STOCH(KDJ)(9,3,3)

7.010

Oversold

ATR(14)

0.043

Low Volatility

CCI(14)

-116.991

Sell

Williams %R

92.326

Oversold

TRIX(12,20)

-1.140

Sell

StochRSI(14)

4.682

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.649

Sell

MA10

0.694

Sell

MA20

0.741

Sell

MA50

0.867

Sell

MA100

0.811

Sell

MA200

0.891

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 23.60%, representing a quarter-over-quarter decrease of 24.63%. The largest institutional shareholder is The Vanguard, holding a total of 1.66M shares, representing 3.95% of shares outstanding, with 9.75% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kingdon Capital Management, L.L.C.

2.24M

The Vanguard Group, Inc.

Star Investors

1.66M

Federated Hermes Global Investment Management Corp.

5.12M

+76.74%

Avidity Partners Management LP

1.23M

Acadian Asset Management LLC

424.50K

-4.19%

Geode Capital Management, L.L.C.

418.46K

-0.24%

Bridgeway Capital Management, LLC

368.18K

+4.16%

Angulo (Gonzalez David)

323.28K

+7.66%

BlackRock Institutional Trust Company, N.A.

334.65K

-19.72%

AMH Equity, Ltd.

261.08K

-58.36%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.27, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 1.37. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.